following a full submission
ivermectin (Soolantra®) is accepted for restricted use within NHS Scotland.
Indication under review: topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.
SMC restriction: the treatment of moderate to severe inflammatory lesions of rosacea where a topical treatment is considered appropriate.
A phase III, randomised study demonstrated ivermectin 10mg/g cream was significantly superior to an antimicrobial cream at reducing the percentage of inflammatory lesions from baseline to week 16.
The submitting company did not submit evidence for SMC assessment for use in patients with mild papulopustular rosacea, therefore SMC cannot recommend ivermectin 10mg/g cream for use in this sub-population.
Download detailed advice175KB (PDF)
- Medicine name:
- ivermectin (Soolantra)
- SMC ID:
- topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.
- Pharmaceutical company
- Galderma (UK) Ltd
- BNF chapter
- Submission type
- Date advice published
- 07 December 2015